Drugs / GSK3810109A
GSK3810109A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03538626 | Jun 2018 → Aug 2022 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04871113 | Jun 2021 → Oct 2022 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3810109A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04871113 ↗ |
| Known as | N6LS | “N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.” NCT03538626 ↗ |
| Known as | VRC-HIVMAB091-00-AB | “N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.” NCT03538626 ↗ |
| Modality | Monoclonal antibody | “N6LS is a human monoclonal antibody.” NCT03538626 ↗ |
| Route | Intravenous | “It was given into a vein in the arm (intravenously, IV) or as an injection underneath the skin (subcutaneously, SC).” NCT03538626 ↗ |
| Route | Subcutaneous | “It was given into a vein in the arm (intravenously, IV) or as an injection underneath the skin (subcutaneously, SC).” NCT03538626 ↗ |